UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Follow the ATP: tumor energy production: a perspective

Anti-cancer agents in medicinal chemistry, 2014-01, Vol.14 (9), p.1187-1198

2014

Volltextzugriff (PDF)

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment

Anti-cancer agents in medicinal chemistry, 2014-01, Vol.14 (8), p.1121-1127

2014

Volltextzugriff (PDF)

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

The lancet oncology, 2015-09, Vol.16 (9), p.1133-1142

2015

Volltextzugriff (PDF)

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review

Translational oncology, 2012-04, Vol.5 (2), p.66-71

2012

Volltextzugriff (PDF)

Rewriting the Epigenetic Code for Tumor Resensitization: A Review

Translational oncology, 2014-10, Vol.7 (5), p.626-631

2014

Volltextzugriff (PDF)

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

PloS one, 2014-07, Vol.9 (7), p.e101626

2014

Volltextzugriff (PDF)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

Neoplasia (New York, N.Y.), 2015-09, Vol.17 (9), p.716-722

2015

Volltextzugriff (PDF)

Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers

Translational oncology, 2011-08, Vol.4 (4), p.189-198

2011

Volltextzugriff (PDF)

The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents

Translational oncology, 2012-08, Vol.5 (4), p.226-229

2012

Volltextzugriff (PDF)

No patient left behind: The promise of immune priming with epigenetic agents

Oncoimmunology, 2017-10, Vol.6 (10), p.e1315486-e1315486

2017

Volltextzugriff (PDF)

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome

Case reports in oncology, 2016-04, Vol.9 (1), p.246-248

2016

Volltextzugriff (PDF)

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

Case reports in oncology, 2016-01, Vol.9 (1), p.68-75

2016

Volltextzugriff (PDF)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Case reports in oncology, 2016-01, Vol.9 (1), p.62-67

2016

Volltextzugriff (PDF)

Episensitization: Defying Time's Arrow

Frontiers in oncology, 2015, Vol.5, p.134-134

2015

Volltextzugriff (PDF)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

Case reports in oncology, 2016-01, Vol.9 (1), p.45-50

2016

Volltextzugriff (PDF)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

Case reports in oncology, 2016-03, Vol.9 (1), p.171-176

2016

Volltextzugriff (PDF)

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001

Clinical Medicine Insights. Oncology, 2016-01, Vol.2016 (10), p.105-108

2016

Volltextzugriff (PDF)

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent

Redox biology, 2015-08, Vol.5, p.422-422

2015

Volltextzugriff (PDF)

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock

Asian journal of transfusion science, 2015-01, Vol.9 (1), p.55-60

2015

Volltextzugriff (PDF)

Light-fluorous safety-catch arylgermanes - exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling

Chemical communications (Cambridge, England), 2007-01 (28), p.2926-2928

2007

Volltextzugriff (PDF)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001

Case reports in oncology, 2016-03, Vol.9 (1), p.164-170

2016

Volltextzugriff (PDF)

Abstract 6381: NBS-1120: An e-NSAID with potent anti-cancer activity targets cell cycle proteins by generating polysulfides

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6381-6381

2020

Volltextzugriff (PDF)

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells

Leukemia, 2016-11, Vol.30 (11), p.2187-2197

2016

Volltextzugriff (PDF)

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Case reports in oncology, 2016-05, Vol.9 (2), p.285-289

2016

Volltextzugriff (PDF)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Case reports in oncology, 2015-10, Vol.8 (3), p.461-465

2015

Volltextzugriff (PDF)

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Englisch
(138)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(58)
Oncology
(38)
Humans
(31)
Animals
(23)
Chemistry
(19)
Physical Sciences
(19)
Rrx-001
(17)
Pharmacology & Pharmacy
(15)
Azetidines - Pharmacology
(14)
Nitro Compounds - Pharmacology
(14)
Antineoplastic Agents - Pharmacology
(12)
Chemistry, Medicinal
(11)
Cancer
(10)
Chemistry, Organic
(10)
Mice
(10)
Review
(10)
Epigenetics
(9)
Male
(9)
Neoplasms - Drug Therapy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Follow the ATP: tumor energy production: a perspective

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review

Rewriting the Epigenetic Code for Tumor Resensitization: A Review

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers

The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents

No patient left behind: The promise of immune priming with epigenetic agents

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Episensitization: Defying Time's Arrow

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock

Light-fluorous safety-catch arylgermanes - exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001

Abstract 6381: NBS-1120: An e-NSAID with potent anti-cancer activity targets cell cycle proteins by generating polysulfides

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Suchergebnisse filtern